Premium
P3‐082: TARGETED METABOLOMICS ON BRAIN AND BLOOD FOR ALZHEIMER'S DISEASE USING LC‐MS/MS METHOD
Author(s) -
Inoue Koichi,
Akatsu Hiroyasu,
Hashizume Yoshio,
Matsukawa Noriyuki,
Yamamoto Takayuki,
Toyo'oka Toshimasa
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.1170
Subject(s) - metabolomics , triple quadrupole mass spectrometer , biomarker discovery , selected reaction monitoring , biomarker , dementia , medicine , disease , omics , computational biology , profiling (computer programming) , bioinformatics , mass spectrometry , proteomics , computer science , chemistry , biology , chromatography , tandem mass spectrometry , biochemistry , gene , operating system
(humanMAP). Linear regressions were utilized with the dependent variable being measured by theWechslerMemory Scale 3 rd Edition, LogicalMemory test, which evaluated immediate and delayed memory. Covariates included gender, age, and education. Results: Among MCI cases without DM, GLP1 was negatively associated with delayed (p-value1⁄4 0.028) memory scores. However, among MCI cases within diabetes GLP-1 levels were positively associated with delayed memory (p-value1⁄40.033). Conclusions: GLP-1 was found to be differentially associated with delayed memory performance among MCI cases depending on DM status. These preliminary studies should be replicated in a larger sample size for confirmation. If confirmed, these results will support the possibility of GLP-1 targeted medications for the treatment of MCI, but only those patients with comorbid diabetes.